Effects of intravenous immunoglobulin on plasma interleukin-10 levels in Kawasaki disease.
Kawasaki disease is an acute febrile disease in children and many inflammatory cytokines are known to be involved in its pathogenesis. Interleukin-10 (IL-10) is an anti-inflammatory cytokine and previous reports have shown blood IL-10 levels were elevated during the acute phase of Kawasaki disease. In this study, we endeavoured to clarify the effects of i.v.IG on plasma IL-10 levels and to verify by RT-PCR, using specific primers, whether viral IL-10 or human IL-10 was responsible for high plasma IL-10. T-cells and B-cells were separated using magnetic beads, and IL-10 mRNA expressions were tested in both cell types. The mean plasma IL-10 levels were significantly decreased from 125.037 +/- 111.161 pg/ml, before i.v.IG treatment, to 32.437 +/- 54.716 pg/ml, after i.v.IG treatment, in subjects with Kawasaki disease. The levels of patients before i.v.IG treatment were significantly higher than those of the acute febrile patients (mean 26.956 +/- 13.316 pg/ml) and the normal controls (mean 16.042 +/- 5.088 pg/ml). RT-PCR was performed using specific primers to distinguish whether viral IL-10 (BCRF-1) or human IL-10 was produced in Kawasaki disease. Viral IL-10 (BCRF-1) mRNA expression was not detected in any groups and only human IL-10 mRNA transcripts were detected in PBMCs of Kawasaki patients as well as in those of acute febrile patients and normal controls. Human IL-10 mRNA transcripts were detected in both CD3+ T-cells and CD19+ B-cells. Elevated IL-10 levels during the acute phase of Kawasaki disease decreased immediately after i.v.IG administration, coincidentally with rapid improvement of inflammatory symptoms. Elevated plasma IL-10 in Kawasaki disease was transcripted from the human IL-10 gene and IL-10 mRNA expressions were detected in both T- and B-cells. Therefore, this study suggests that plasma IL-10 levels may be useful in the early identification and discrimination of the acute phase of Kawasaki disease from other febrile diseases. However, i.v.IG effects on IL-10 production still needs further investigation.
Noh
G W
GW
Department of Pediatrics, Sungkyunkwan University, College of Medicine, Samsung Cheil Hospital, Women's Healthcare Centre, Seoul, South Korea.
Lee
W G
WG
Lee
W
W
Lee
K
K
D001402:B-Lymphocytes / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000097:blood* / Q000235:genetics; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D012333:RNA, Messenger; D013601:T-Lymphocytes / Q000378:metabolism
D016756:Immunoglobulins, Intravenous; D012333:RNA, Messenger; D016753:Interleukin-10